Harmony Biosciences (HRMY)

Executive Summary

Harmony Biosciences is a commercial-stage biopharmaceutical company focused on rare neurological diseases, with a patient-centric approach termed 'Newrology.' Its lead product, pitolisant (Wakix), is approved for narcolepsy with or without cataplexy and has generated substantial revenue, providing a strong financial base. The company is expanding its pipeline into rare epilepsies (clemizole HCl for Dravet and Lennox-Gastaut syndromes) and other sleep/wake disorders (pitolisant for idiopathic hypersomnia and Prader-Willi syndrome). Harmony's strategy leverages its established commercial infrastructure and regulatory expertise to address high-unmet-need indications. Key near-term catalysts include a potential FDA decision on pitolisant for idiopathic hypersomnia, following positive Phase 3 data, which could significantly expand the addressable market. Additionally, ongoing Phase 3 trials for pitolisant in Prader-Willi syndrome and clemizole in Dravet syndrome are advancing, with data readouts anticipated in the coming years. The company's strong balance sheet and growing revenue from Wakix provide a buffer against pipeline risk, making it an attractive investment in the rare disease space.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on pitolisant for idiopathic hypersomnia65% success
• 2027Phase 3 data readout for pitolisant in Prader-Willi syndrome40% success
• TBDPhase 3 interim analysis for clemizole in Dravet or Lennox-Gastaut syndromes35% success